CCL2 and COVID-19: An increase in serum MCP-1 was observed in acute COVID-19 and even more in MIS-C children [21], and another study reported the increase in serum MCP-1 in MIS-C patients with the reversion to normal levels after methylprednisone treatment by the fifth day of the disease [22].